UK: Precision Nanoparticles Dolomite and Mologic Collaborate to Develop Rapid Covid-19 Diagnostic Tests
Mologic has recently received funding from the UK Government to develop a test for Covid-19 which can generate results within minutes. For this purpose, the company has tied up with Dolomite Microfluidics in order to scale-up precision nanoparticles which are vital for this project.
UK – As the Covid-19 pandemic progresses in countries around the globe, there is an urgent need for rapid and reliable point-of-need detection testing. Dolomite Microfluidics and Mologic are working together to accelerate the development and launch of these tests.
UK-based company Mologic is a leading developer of rapid response diagnostic tests for diseases such as malaria and Ebola virus disease. Clients include the Bill & Melinda Gates Foundation, where Mologic is leveraging its core technology through its Centre for Advanced Rapid Diagnostics (Card) to develop the next generation of ultra-sensitive point-of-care diagnostics which are easy to use and inexpensive to manufacture – critical to the success of many global health programmes.
Most recently, Mologic has received UK Government funding to develop and manufacture a high sensitivity test for Covid-19 that generates results within minutes – rather than hours or days – without the need for a laboratory or specialist equipment.
The technology behind these tests involves the use of precisely manufactured nanoparticles. Dolomite specialises in equipment that allows the development and scale-up of precision nanoparticles. This is achieved by using microfluidic technology to retain advanced control of production conditions.
Dolomite is working with Mologic to combine ground-breaking diagnostic technology with continuous flow microfluidic manufacturing processes to accelerate the validation and release of Mologic’s Covid-19 diagnostic test.